GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » PS Ratio

Titan Pharmaceuticals (Titan Pharmaceuticals) PS Ratio : (As of May. 07, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Titan Pharmaceuticals's share price is $6.88. Titan Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Hence, Titan Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Titan Pharmaceuticals's PS Ratio or its related term are showing as below:

TTNP' s PS Ratio Range Over the Past 10 Years
Min: 0.44   Med: 8.14   Max: 9290
Current: 6880

During the past 13 years, Titan Pharmaceuticals's highest PS Ratio was 9290.00. The lowest was 0.44. And the median was 8.14.

TTNP's PS Ratio is ranked worse than
98.9% of 996 companies
in the Biotechnology industry
Industry Median: 9.19 vs TTNP: 6880.00

Titan Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Warning Sign:

Titan Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Titan Pharmaceuticals was -98.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -96.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -92.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -71.30% per year.

During the past 13 years, Titan Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 1559.70% per year. The lowest was -96.60% per year. And the median was -31.15% per year.

Back to Basics: PS Ratio


Titan Pharmaceuticals PS Ratio Historical Data

The historical data trend for Titan Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals PS Ratio Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 2.57 39.92 175.98 8,250.00

Titan Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.98 210.13 170.05 133.52 -

Competitive Comparison of Titan Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Titan Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's PS Ratio falls into.



Titan Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Titan Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=6.88/0.001
=

Titan Pharmaceuticals's Share Price of today is $6.88.
Titan Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Titan Pharmaceuticals  (NAS:TTNP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Titan Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080